FMC (FMC)
Develops and sells crop-protection products for growers worldwide.
Something off on this page? Send us feedback.
Sells insecticides, herbicides, fungicides, biologicals, crop nutrition, and seed treatments through one global agricultural-sciences segment. Its portfolio combines conventional chemistry with plant-health products and depends on product registrations, intellectual property, manufacturing inputs, and access to growers.
Operates one global agricultural-sciences segment supplying insecticides, herbicides, fungicides, biologicals, crop nutrition, and seed-treatment products, grouped as plant health. Products serve growers across North America, Latin America, EMEA, and Asia.
Research focuses on discovering insecticide, herbicide, and fungicide active ingredients. The portfolio expanded through Cheminova, DuPont crop-protection assets, and BioPhero, combining conventional chemicals with biological and pheromone capabilities.
The business depends on registrations, intellectual property, discovery and development, manufacturing inputs, and access to growers across regions. It also plans to divest its India commercial business while retaining active-ingredient manufacturing there.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 11, 2026 | KeyBanc | Initiate | Rating: —Target: $81 | Target: $16 |
| Aug 4, 2026 | Seaport Global | Target | Target: $55 | Target: $21 |
| Aug 3, 2026 | RBC Capital | Reiterate | Rating: —Target: $14 | Target: $11 |
| Jul 31, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $15.50 | Target: $12 |
| Jul 31, 2026 | Goldman Sachs | Reiterate | Rating: —Target: $43 | Target: $18 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $476.6M · Total debt $4.28B · Total assets $9.14B · Shareholders' equity $1.64B
- Revenue
- $867.1M
- Operating income
- −$119.7M
- Net income
- −$186.6M
HistoryDividendAnnual yieldUpcoming
| Institutions | ≈ 105.66% | 132.32M shares | |
|---|---|---|---|
| 439 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.14% | 1.43M shares | |
| 23 holders · as of Sep 10, 2026 | |||
| Adds to | 106.80% | ||
125.23M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 106.80%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 17.20% | 21.54M | as of Jun 30, 2026 |
AQR Capital Management LLCInstitution | 6.41% | 8.02M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 6.16% | 7.72M | as of Jun 30, 2026 |
State Street CorpInstitution | 5.20% | 6.51M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.60% | 5.76M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 9, 2026 | Nicholas Pfeiffer | officer: Corporate Controller | −1,251 | $12.78 |
| Mar 4, 2026 | Michael F. Barry | director | +18,072 | $13.83 |
| Nov 13, 2025 | John Mitchell Raines | director | +7,000 | $13.77 |
| Nov 5, 2025 | Carol Anthony Davidson | director | +10,000 | $13.60 |
| Sep 29, 2025 | Jacqueline Scanlan | officer: Executive VP & Chief HRO | −3,790 | $34.00 |
